Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Bioanalysis
|
May 10, 2019
Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor
Jens C Göpfert, Astrid Reiser, Viviana A Carcamo Yañez, et al.
Journal of Pharmaceutical Sciences
|
April 4, 2021
Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside
Katharine Bray-French, Katharina Hartman, Guido Steiner, et al.
The Journal of Biological Chemistry
|
December 23, 2008
CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability
Changhua Ji, Erhard Kopetzki, Andreas Jekle, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
February 12, 2015
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies
Stefan Dengl, Eike Hoffmann, Michael Grote, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
Sophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy
Yvonne Kienast, Christian Klein, Werner Scheuer, et al.
Frontiers in Immunology
|
June 17, 2024
Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure
Gregor P Lotz, Achim Lutz, Meret Martin-Facklam, et al.
Biological Chemistry
|
January 24, 2022
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
Steffen Dickopf, Can Buldun, Vedran Vasic, et al.
Molecular Therapy. Methods & Clinical Development
|
September 12, 2022
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong-Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Nature Communications
|
June 26, 2020
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
Martina Geiger, Kay-Gunnar Stubenrauch, Johannes Sam, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Bioanalysis
|
May 10, 2019
Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor
Jens C Göpfert, Astrid Reiser, Viviana A Carcamo Yañez, et al.
Journal of Pharmaceutical Sciences
|
April 4, 2021
Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside
Katharine Bray-French, Katharina Hartman, Guido Steiner, et al.
The Journal of Biological Chemistry
|
December 23, 2008
CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability
Changhua Ji, Erhard Kopetzki, Andreas Jekle, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
February 12, 2015
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies
Stefan Dengl, Eike Hoffmann, Michael Grote, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
Sophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy
Yvonne Kienast, Christian Klein, Werner Scheuer, et al.
Frontiers in Immunology
|
June 17, 2024
Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure
Gregor P Lotz, Achim Lutz, Meret Martin-Facklam, et al.
Biological Chemistry
|
January 24, 2022
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
Steffen Dickopf, Can Buldun, Vedran Vasic, et al.
Molecular Therapy. Methods & Clinical Development
|
September 12, 2022
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong-Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Nature Communications
|
June 26, 2020
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
Martina Geiger, Kay-Gunnar Stubenrauch, Johannes Sam, et al.
Page
of 3